Dr. Falk Pharma Australia – the experts in digestive and metabolic medicine

Learn more

Innovation drives everything we do

Dr. Falk Pharma – Innovation drives everything

As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. For over 60 years. 
Our focus: To enable relief, well-being, more ease of movement and confidence in everyday situations for millions of people with inflammatory bowel disease as well as digestive and metabolic problems. With the best possible therapies.

About us

Our products

For the treatment of inflammatory bowel disease, cholestatic liver diseases, eosinophilic oesophagitis, and other diseases

Discover products

Knowledge drives everything

Falk Foundation – scientific dialogue to advance therapeutic progress

Learn more

The diseases we treat

Find in-depth information about chronic diseases of the intestines, oesophagus, and bile ducts.

Learn more
Prometheus Logo
Corporate, Press release

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment


SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…


Corporate, Press release

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy


Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of…


Corporate, Press release

First patient treated in phase iib study of Naronapride in patients with gastroparesis


Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…